NCT05582551 Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors
| NCT ID | NCT05582551 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Childhood Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 146 participants |
| Start Date | 2023-08-02 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 146 participants in total. It began in 2023-08-02 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of this study is to attempt to overcome the organizational barriers that impede prompt screening for at-risk sensory deficits in childhood cancer survivors (CCS). Using a cross sectional design study, collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the highlighting patients at risk for sensory screening (HPARSS) document. The investigators will utilize the HPARSS that will link therapy related risks for sensory deficits to specific screening procedures prompting the primary oncology provider to implement screening, diagnostic testing, and therapy.
Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis of pediatric cancer (diagnosis at \<18 years of age) * Treatment including chemotherapy and/or radiation therapy * Completion of all cancer therapy for at least 6 months and less than 2 years * Followed in the Division of Pediatric Hematology/Oncology Program at the Washington University School of Medicine * Current age between 7 and 17 years of age (age where all of the screening tests are both valid and have been successfully performed by our group) * English speaking Exclusion Criteria: * Undergoing active cancer treatment * Patient under the care of the Late Effects Program at St. Louis Children's Hospital * Received previous diagnostic testing or rehabilitative therapy for a secondary deficit eligible for screening. * Parents and/or patient illiteracy * No contact with treatment team in the past two years * In foster care or without a legal guardian
Contact & Investigator
Robert J Hayashi, M.D.
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT05582551 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 17 Years, studying Childhood Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05582551 currently recruiting?
Yes, NCT05582551 is actively recruiting participants. Contact the research team at hayashi_r@wustl.edu for enrollment information.
Where is the NCT05582551 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT05582551 clinical trial?
NCT05582551 is sponsored by Washington University School of Medicine. The principal investigator is Robert J Hayashi, M.D. at Washington University School of Medicine. The trial plans to enroll 146 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.